WHO study finds no benefit from remdesivir on COVID-19 deaths, hospital stays
The antiviral drug remdesivir had no substantial impact on the survival of COVID-19 patients or the length of their hospital stays, according to a World Health Organization (WHO) clinical trial.
Source: TEST FEED1